NFKB1 and glioblastoma: To date, studies examining NF‐κB as a potential therapeutic target have focused on non‐specific agents or on targets such as IκK that affect multiple signalling pathways.2 However, although a number of approaches targeting NF‐κB have shown promise in pre‐clinical GBM models, the strategies that have been tested in clinical settings have thus far not shown satisfactory advantages over other approaches.5 Therefore, strategies that manipulate specific subsets of NF‐κB signalling may be more successful for treating GBM.2